Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity
Journal of Immunology Research · 2023
DOI: 10.1155/2023/2344239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Immunology Research, 2023. Verfasst von Fulvia Ceccarelli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Lupus Clinic, Rheumatology Unit, Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, …. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The role of T cells in the pathogenesis of systemic lupus erythematosus (SLE) has recently gained attention. Costimulatory molecules are membrane proteins strictly associated with T-cell receptor (TCR), acting by activating or inhibiting T cells and antigen-presenting cells (APC) through direct and reverse signaling, thus becoming responsible for the development of effector T cells or regulatory T cells. The primary objective of the present case–control study was to evaluate the cell membrane expression of CD137 on T cells and the serum concentration of CD137 (sCD137) in a SLE cohort. Materials. We enrolled SLE patients and sex/age-matched healthy subjects (HS). Disease activity was assessed by SLEDAI-2K. By application of flow cytometry, we evaluated the expression of CD137 on CD4+ and CD8+ lymphocytes. ELISA test was performed to evaluate serum levels of sCD137.
Results
Twenty-one SLE patients (M/F 1/20; median age 48 years (IQR 17); median disease duration 144 months (IQR 204)) were evaluated. SLE patients showed %CD3+CD137+ cells significantly higher compared to HS (median 5.32 (IQR 6.11) versus 3.3 (IQR 1.8), p = 0.001 ). In SLE patients, %CD4+CD137+ cells positively correlated with SLEDAI-2K ( p = 0.0082 , r = 0.58, CI (0.15–0.82); indeed, %CD4+CD137+ cells were significantly lower in SLE patients with a remission status compared to those not reaching this condition (median 1.07 (IQR 0.91) versus 1.58 (IQR 2.42), p = 0.013 ). Accordingly, sCD137 levels were significantly lower in remission status (31.30 pg/mL (IQR 102.2 versus median 122.8 pg/mL (IQR 536); p = 0.03 ) and correlated with %CD4+CD137+ cells ( p = 0.012 , r = 0.60, CI (0.15–0.84)).
Conclusion
Our results suggest a possible involvement of CD137-CD137L axis in SLE pathogenesis, as demonstrated by higher expression of CD137 on CD4+ cells in SLE compared with HS. Furthermore, the positive correlation between SLEDAI-2K and membrane CD137 expression on CD4+ cells, as well as soluble CD137, indicates a possible use as biomarkers for disease activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lupus Clinic, Rheumatology Unit, Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
- Laboratory of Tumor Immunology and Cell Therapy, Department of Experimental Medicine, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
ORCID-Profile: Aurelia Rughetti, Ilaria Grazia Zizzari
Zitieren
APA
Ceccarelli, F., Natalucci, F., Di Filippo, A., Olivieri, G., Napoletano, C., Rughetti, A., Nuti, M., Zizzari, I. G., & Conti, F. (2023). Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity. Journal of Immunology Research. https://doi.org/10.1155/2023/2344239
Vancouver
Ceccarelli F, Natalucci F, Di Filippo A, Olivieri G, Napoletano C, Rughetti A, et al. Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity. Journal of Immunology Research. 2023. doi:10.1155/2023/2344239
BibTeX
@article{Ceccarelli2023,
author = {Ceccarelli, Fulvia and Natalucci, Francesco and Di Filippo, Alessandra and Olivieri, Giulio and Napoletano, Chiara and Rughetti, Aurelia and Nuti, Marianna and Zizzari, Ilaria Grazia and Conti, Fabrizio},
title = {Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity},
journal = {Journal of Immunology Research},
year = {2023},
doi = {10.1155/2023/2344239}
}
EUVIMED